EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
18-Dec-2023 / 08:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI)
announces that the Company considers strategic options for its Carragelose
business and has mandated an external advisor. A structured process was
initiated, in which Marinomed and the advisor will start engaging with
potential partners.
The Company is continuously evaluating the business to enable the best
possible future growth. Regulatory changes in the coming year will also be
included in the evaluation, which are expected to have a positive impact
on the Company’s business, particularly with regard to Carragelose
products. The evaluation process may include strategic partnerships and
the consideration of transferring the Carragelose portfolio to a partner
that could maximize its value enabling the Company to increase its focus
on the Marinosolv platform.
+++ End of the ad hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
18-Dec-2023 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1798437
End of Announcement EQS News Service
1798437 18-Dec-2023 CET/CEST